NCT05062304View on ClinicalTrials.gov

Replication of the IMPACT COPD Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

17,281

Participants

Timeline

Start Date

December 13, 2020

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions
COPD
Interventions
DRUG

Fluticasone Furoate-Vilanterol Trifenatate

Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.

DRUG

Furoate-umeclidinium-vilanterol

Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT05062304 - Replication of the IMPACT COPD Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter